May 13th 2024
A large study finds that obesity and metabolic syndrome raise breast cancer mortality risk, but through different mechanisms. Metabolic syndrome is linked to a specific type of breast cancer, whereas obesity increases risk across all breast cancer subtypes.
Dr Alexey Aleshin Highlights the Diagnostic Benefits of ctDNA in Early-Stage Breast Cancer
December 12th 2020Circulating tumor DNA (ctDNA) has a host of benefits in treating and managing patients with early-stage disease, noted Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera.
Watch
Obesity May Fuel 40% Gap in Black, White Breast Cancer Mortality
December 7th 2020Overall survival from early breast cancer has steadily been increasing; however, simultaneous increases in obesity and obesity-related comorbidities may have contributed to the survival disparity seen between these patient groups.
Read More
Dr Aditya Bardia Highlights Immuno-Oncology Developments for Patients With TNBC
November 25th 2020Tecentriq (atezolizumab) was approved in 2019 for PD-L1–positive triple-negative breast cancer (TNBC), said Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.
Watch
Bilateral Mastectomy Possibly Linked to Poor Self-Image Among Young Breast Cancer Survivors
November 10th 2020A recent study of female breast cancer survivors shows that feelings toward body image were consistently worse among those who had a bilateral mastectomy vs breast-conserving surgery.
Read More
Study Results Point to Possible Survival Link Between Elderly Age, Chemotherapy
November 7th 2020Having node-positive, estrogen receptor–positive breast cancer indicated a greater likelihood of overall survival following chemotherapy, despite having several comorbidities, after adjustment for confounders.
Read More
Dr Aditya Bardia: Further Research Is Needed to Understand Resistance to Sacituzumab Govitecan
November 1st 2020Despite FDA accelerated approval in April, we still need to learn more about resistance to this antibody drug conjugate, said Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.
Watch
Axillary Surgery Approach Impacts BCRL Risk in Breast Cancer Patients
October 28th 2020A study published in the Journal of Clinical Oncology determined that the main risk factor for breast cancer-related lymphedema in patients with positive axillary lymph nodes is the type of axillary surgery used.
Read More
Dr Aditya Bardia Forecasts What’s to Come for the ASCENT Trial in Triple-Negative Breast Cancer
October 25th 2020Initial preliminary efficacy and safety data are expected sometime next year, stated Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.
Watch
This Week in Managed Care: October 23, 2020
October 23rd 2020This week, the top managed care news included COVID-19 delays in breast cancer surgery; targeted therapies associated with decreased mortality risk for non–small cell lung cancer; an inside look at a patient’s perspective of early-onset Parkinson disease.
Watch
Dr Timothy Yap Reiterates the Unmet Medical Need for Molecularly Targeted Agents in Solid Tumors
October 19th 2020Early results on rucaparib/sacituzumab govitecan are promising, but further exploration is needed, stated Timothy A. Yap, MBBS, PhD, FRCP, medical director of the Institute for Applied Cancer Science, MD Anderson Cancer Center.
Watch
Dr Aditya Bardia on How Combining Sacituzumab Govitecan, Talazoparib Amplifies Treatment Response
October 12th 2020There is a synthetic lethality between sacituzumab govitecan and a PARP inhibitor, noted Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.
Watch
Dr Timothy Yap: PARP/TOP1 Inhibitor Toxicities Can Be Managed Through Targeted Delivery
October 5th 2020Targeted tumor delivery of irinotecan through sacituzumab govitecan can help to reduce treatment-related toxicities, noted Timothy A. Yap, MBBS, PhD, FRCP, medical director of the Institute for Applied Cancer Science, MD Anderson Cancer Center.
Watch
Mortality Higher Among Women With Interval vs Screening-Detected Breast Cancers
October 1st 2020Results from a study on Canadian women who did and did not participate in a population-based breast cancer screening program show that interval breast cancers are more aggressive and deadlier than screening-detected cancers.
Read More
Dr Aditya Bardia Discusses the Advantages of Sacituzumab Govitecan for Triple-Negative Breast Cancer
September 28th 2020There is a clear need for better therapies to treat triple-negative breast cancer, especially when progression-free survival is around 2%, says Aditya Bardia, MBBS, MPH, breast medical oncologist at Massachusetts General Hospital, Harvard Medical School.
Watch
Dr Timothy Yap: Rucaparib/Sacituzumab Govitecan Combo Effective Against Triple-Negative Disease
September 25th 2020A novel combination shows promise against advanced solid tumors, including triple-negative breast cancer, noted Timothy A. Yap, MBBS, PhD, FRCP, medical director of the Institute for Applied Cancer Science at MD Anderson Cancer Center.
Watch
Possible Link Found Between Breast Cancer Mortality and Childhood Radiation Treatment
September 11th 2020Study results show that among premenopausal women, adulthood second primary breast cancer may carry with it a 2-fold greater risk of death if they had undergone radiation treatment for cancer as a child or young adult.
Read More
Early-Onset Breast Cancer Possibly Linked to Preeclamptic Pregnancy, High Birth Weight
September 6th 2020With little research on the subject, the investigators sought out a connection between certain perinatal factors and risk of young-onset breast cancer in a sister-matched case-control study.
Read More